Protocol Details BPC-157 and TB-500 are administered via subcutaneous injection, typically on a daily or alternating-day schedule depending on the severity of the condition
- Pregnancy and breast-feeding: As there is no established safety data for MOTS-c use during pregnancy or breast-feeding, it should be avoided
Product specifications Description All presented information is based on scientific publications which can be found at the end of product description below
For researchers who tolerate 8mg well and want to minimize side effects while still targeting significant fat loss , maintaining at 8mg rather than escalating to 12mg is a legitimate choice, and the 20mg/mL concentration serves both maintenance levels equally well
The trial evaluated multiple dosing cohorts with an escalation schedule designed to minimize gastrointestinal side effects during the initial weeks of treatment: Key Observations From Retatrutide Dosage Data Dose-dependent response Weight reduction increased in a clear dose-dependent pattern across all cohorts
At 30 mg/mL, a single unit on your syringe represents 0.3 mg of tirzepatide
